| pubmed-article:10347750 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10347750 | lifeskim:mentions | umls-concept:C0020971 | lld:lifeskim |
| pubmed-article:10347750 | lifeskim:mentions | umls-concept:C0282641 | lld:lifeskim |
| pubmed-article:10347750 | lifeskim:mentions | umls-concept:C0314603 | lld:lifeskim |
| pubmed-article:10347750 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:10347750 | lifeskim:mentions | umls-concept:C0851285 | lld:lifeskim |
| pubmed-article:10347750 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:10347750 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:10347750 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10347750 | pubmed:dateCreated | 1999-8-31 | lld:pubmed |
| pubmed-article:10347750 | pubmed:abstractText | The use of mammalian gene expression vectors has become increasingly important for genetic immunization and gene therapy as well as basic research. Essential for the success of these vectors in genetic immunization is the proper choice of a promoter linked to the antigen of interest. Many genetic immunization vectors use promoter elements from pathogenic viruses including SV40 and CMV. Lymphokines produced by the immune response to proteins expressed by these vectors could inhibit further transcription initiation by viral promoters. Our objective was to determine the effect of IFN-gamma on transgene expression driven by viral SV40 or CMV promoter/enhancer and the mammalian promoter/enhancer for the major histocompatibility complex class I (MHC I) gene. We transfected the luciferase gene driven by these three promoters into 14 cell lines of many tissues and several species. Luciferase assays of transfected cells untreated or treated with IFN-gamma indicated that although the viral promoters could drive luciferase production in all cell lines tested to higher or lower levels than the MHC I promoter, treatment with IFN-gamma inhibited transgene expression in most of the cell lines and amplification of the MHC I promoter-driven transgene expression in all cell lines. These data indicate that the SV40 and CMV promoter/enhancers may not be a suitable choice for gene delivery especially for genetic immunization or cancer cytokine gene therapy. The MHC I promoter/enhancer, on the other hand, may be an ideal transgene promoter for applications involving the immune system. | lld:pubmed |
| pubmed-article:10347750 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10347750 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10347750 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10347750 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10347750 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10347750 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10347750 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10347750 | pubmed:issn | 0100-879X | lld:pubmed |
| pubmed-article:10347750 | pubmed:author | pubmed-author:SplitterG AGA | lld:pubmed |
| pubmed-article:10347750 | pubmed:author | pubmed-author:HarmsJ SJS | lld:pubmed |
| pubmed-article:10347750 | pubmed:author | pubmed-author:OliveiraS CSC | lld:pubmed |
| pubmed-article:10347750 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10347750 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:10347750 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10347750 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10347750 | pubmed:pagination | 155-62 | lld:pubmed |
| pubmed-article:10347750 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:meshHeading | pubmed-meshheading:10347750... | lld:pubmed |
| pubmed-article:10347750 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10347750 | pubmed:articleTitle | Regulation of transgene expression in genetic immunization. | lld:pubmed |
| pubmed-article:10347750 | pubmed:affiliation | Department of Animal Health and Biomedical Sciences, University of Wisconsin, Madison, USA. harms@ahabs.wisc.edu | lld:pubmed |
| pubmed-article:10347750 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10347750 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10347750 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10347750 | lld:pubmed |
